MA46679B1 - Sels très hydrosolubles d'un inhibiteur des canaux calciques à base de phénylalkylamine à action courte et leurs utilisations - Google Patents

Sels très hydrosolubles d'un inhibiteur des canaux calciques à base de phénylalkylamine à action courte et leurs utilisations

Info

Publication number
MA46679B1
MA46679B1 MA46679A MA46679A MA46679B1 MA 46679 B1 MA46679 B1 MA 46679B1 MA 46679 A MA46679 A MA 46679A MA 46679 A MA46679 A MA 46679A MA 46679 B1 MA46679 B1 MA 46679B1
Authority
MA
Morocco
Prior art keywords
water soluble
calcium channel
soluble salts
channel blocker
highly water
Prior art date
Application number
MA46679A
Other languages
English (en)
Other versions
MA46679A (fr
Inventor
Martin P Maguire
Original Assignee
Milestone Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57125495&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA46679(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Milestone Pharmaceuticals Inc filed Critical Milestone Pharmaceuticals Inc
Publication of MA46679A publication Critical patent/MA46679A/fr
Publication of MA46679B1 publication Critical patent/MA46679B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des sels étonnamment hydrosolubles d'un composé de phénylalkylamine qui sont de puissants antagonistes de canaux calciques de type l. Des solutions aqueuses comprenant des sels de la présente invention sont formulées pour l'administration par voie nasale et offrent une nouvelle plate-forme thérapeutique pour le traitement de l'angine de poitrine stable, de la migraine, et l'arythmie cardiaque, comme la tachycardie supraventriculaire paroxystique.
MA46679A 2015-04-14 2016-04-13 Sels très hydrosolubles d'un inhibiteur des canaux calciques à base de phénylalkylamine à action courte et leurs utilisations MA46679B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562147427P 2015-04-14 2015-04-14
PCT/CA2016/050425 WO2016165014A1 (fr) 2015-04-14 2016-04-13 Sels très hydrosolubles d'un inhibiteur des canaux calciques à base de phénylalkylamine à action courte et leurs utilisations

Publications (2)

Publication Number Publication Date
MA46679A MA46679A (fr) 2018-02-21
MA46679B1 true MA46679B1 (fr) 2020-04-30

Family

ID=57125495

Family Applications (2)

Application Number Title Priority Date Filing Date
MA46679A MA46679B1 (fr) 2015-04-14 2016-04-13 Sels très hydrosolubles d'un inhibiteur des canaux calciques à base de phénylalkylamine à action courte et leurs utilisations
MA052480A MA52480A (fr) 2015-04-14 2016-04-13 Sels hautement solubles dans l'eau d'un agent bloquant les canaux calciques à base de phénylalkylamine à brève durée d'action et leurs utilisations

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA052480A MA52480A (fr) 2015-04-14 2016-04-13 Sels hautement solubles dans l'eau d'un agent bloquant les canaux calciques à base de phénylalkylamine à brève durée d'action et leurs utilisations

Country Status (28)

Country Link
US (13) US10117848B2 (fr)
EP (3) EP3283067B1 (fr)
JP (1) JP6785792B2 (fr)
KR (3) KR102653347B1 (fr)
CN (2) CN113694019A (fr)
AU (1) AU2016249030B2 (fr)
BR (1) BR112017021620B1 (fr)
CA (2) CA2982622C (fr)
CY (1) CY1122931T1 (fr)
DK (1) DK3283067T3 (fr)
ES (2) ES2986137T3 (fr)
HR (1) HRP20200444T1 (fr)
HU (1) HUE049570T2 (fr)
IL (1) IL254889B (fr)
LT (1) LT3283067T (fr)
MA (2) MA46679B1 (fr)
MD (1) MD3283067T2 (fr)
ME (1) ME03679B (fr)
MX (1) MX372659B (fr)
PL (2) PL3689344T3 (fr)
PT (2) PT3283067T (fr)
RS (1) RS60154B1 (fr)
RU (1) RU2731918C2 (fr)
SI (1) SI3283067T1 (fr)
SM (1) SMT202000149T1 (fr)
UA (1) UA121330C2 (fr)
WO (1) WO2016165014A1 (fr)
ZA (2) ZA201706648B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12257224B2 (en) 2021-07-15 2025-03-25 Milestone Pharmaceuticals Inc. Methods of administration for highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker
TW202506649A (zh) 2023-03-31 2025-02-16 南韓商Ｌｇ化學股份有限公司 作為自分泌運動因子（ａｕｔｏｔａｘｉｎ）抑制劑的新穎苯並咪唑酮衍生化合物
WO2025215083A1 (fr) 2024-04-10 2025-10-16 Dipharma Francis S.R.L. Procédé de préparation d'un médicament utilisé pour une tachycardie paroxystique supraventriculaire
WO2025229679A1 (fr) * 2024-04-30 2025-11-06 Cipla Limited Procédé de synthèse d'étripamil

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9605074D0 (en) * 1996-03-11 1996-05-08 Chiroscience Ltd Dosage forms and uses
CA2446904A1 (fr) * 2001-05-24 2003-04-03 Alexza Pharmaceuticals, Inc. Administration d'esters medicamenteux par inhalation
US6831663B2 (en) * 2001-05-24 2004-12-14 Microsoft Corporation System and process for automatically explaining probabilistic predictions
US20050191245A1 (en) * 2004-02-27 2005-09-01 Adams Christopher P. Nasal administration of calcium channel, blockers for treatment of hypertension and other cardiovascular disorders
WO2008019106A1 (fr) * 2006-08-04 2008-02-14 Artesian Therapeutics, Inc. Méthodes et compositions pour le traitement d'hypertension pulmonaire utilisant une combinaison d'un agent bloquant de canal calcium et un inhibiteur de phosphodiestérase
PL2170050T3 (pl) * 2007-06-20 2014-12-31 Milestone Pharmaceuticals Inc Krótkodziałające fenyloalkiloaminowe blokery kanału wapniowego i ich zastosowania
US20090318413A1 (en) * 2008-06-18 2009-12-24 Universite Victor Segalen Bordeaux 2 Bronchial smooth muscle remodeling involves calcium-dependent enhanced mitochondrial biogenesis in asthma
US8974828B2 (en) * 2009-03-18 2015-03-10 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration

Also Published As

Publication number Publication date
UA121330C2 (uk) 2020-05-12
PL3283067T3 (pl) 2020-09-21
SI3283067T1 (sl) 2020-07-31
AU2016249030B2 (en) 2020-08-27
CA2982622A1 (fr) 2016-10-20
IL254889B (en) 2021-07-29
US20190269643A1 (en) 2019-09-05
US20180110752A1 (en) 2018-04-26
US20210205258A1 (en) 2021-07-08
EP4428119A2 (fr) 2024-09-11
KR20180019508A (ko) 2018-02-26
RS60154B1 (sr) 2020-05-29
MA46679A (fr) 2018-02-21
US20240277652A1 (en) 2024-08-22
EP3283067B1 (fr) 2020-01-01
HK1249417A1 (en) 2018-11-02
US20230157990A1 (en) 2023-05-25
MD3283067T2 (ro) 2020-05-31
US20190022048A1 (en) 2019-01-24
CN113694019A (zh) 2021-11-26
KR102653347B1 (ko) 2024-04-02
MX2017013355A (es) 2019-01-21
ES2778673T3 (es) 2020-08-11
US20250332137A1 (en) 2025-10-30
CN107613970A (zh) 2018-01-19
DK3283067T3 (da) 2020-03-30
HUE049570T2 (hu) 2020-10-28
EP3689344A1 (fr) 2020-08-05
JP6785792B2 (ja) 2020-11-18
US10117848B2 (en) 2018-11-06
US20250090488A1 (en) 2025-03-20
ZA201706648B (en) 2020-01-29
RU2017134553A3 (fr) 2019-11-13
CY1122931T1 (el) 2021-10-29
US20230414553A1 (en) 2023-12-28
MA52480A (fr) 2022-03-09
US20200368195A1 (en) 2020-11-26
EP3689344B1 (fr) 2024-06-05
KR20250057109A (ko) 2025-04-28
ZA201807495B (en) 2024-04-24
ME03679B (fr) 2020-10-20
WO2016165014A1 (fr) 2016-10-20
RU2731918C2 (ru) 2020-09-09
AU2016249030A1 (en) 2017-10-26
RU2017134553A (ru) 2019-04-05
IL254889A0 (en) 2017-12-31
EP3283067A1 (fr) 2018-02-21
NZ736249A (en) 2024-07-05
MX372659B (es) 2020-03-26
CN107613970B (zh) 2021-10-19
SMT202000149T1 (it) 2020-05-08
CA3203288A1 (fr) 2016-10-20
ES2986137T3 (es) 2024-11-08
JP2018514527A (ja) 2018-06-07
CA2982622C (fr) 2023-08-22
LT3283067T (lt) 2020-06-25
PL3689344T3 (pl) 2024-11-04
US20200121631A1 (en) 2020-04-23
US20220296556A1 (en) 2022-09-22
HRP20200444T1 (hr) 2020-06-12
PT3689344T (pt) 2024-09-04
EP4428119A3 (fr) 2024-11-13
EP3283067A4 (fr) 2018-12-05
KR20240044546A (ko) 2024-04-04
BR112017021620A2 (pt) 2018-07-03
US20220040139A1 (en) 2022-02-10
BR112017021620B1 (pt) 2023-10-03
PT3283067T (pt) 2020-03-31

Similar Documents

Publication Publication Date Title
JO3653B1 (ar) ترايازول عوامل مساعدة لمستقبل apj
JOP20180009A1 (ar) مركبات مثبط فيروس hiv
MX2024009886A (es) Derivados de quinolina como inhibidores de integrina alfa4beta7.
EA201891703A1 (ru) Соединения бензопиразола и их аналоги
MA38398B1 (fr) Composés biaryle amides en tant qu'inhibiteurs de kinase
JOP20190174B1 (ar) مثبطات jak1 انتقائية
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
MX390302B (es) Oxiesteroles y metodos de uso de los mismos
MA46679B1 (fr) Sels très hydrosolubles d'un inhibiteur des canaux calciques à base de phénylalkylamine à action courte et leurs utilisations
EA201992542A1 (ru) Фармацевтическая композиция для местного применения, содержащая, по меньшей мере, амитриптилин, для лечения периферической нейропатической боли
EA201492091A1 (ru) Фармацевтические композиции для местного применения, содержащие тербинафид и мочевину
MA47736B1 (fr) Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1
MA39152B1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
MA39983B1 (fr) Dérivés de carboxamide
PH12016501198A1 (en) Compounds and compositions for the treatment of parasitic diseases
PH12020550763A1 (en) Pyridinone derivatives and their use as selective alk-2 inhibitors
EA201991688A1 (ru) Фармацевтические комбинации для лечения рака
BR112017014016A2 (pt) método de redução da pressão intraocular, e, composição farmacêutica.
EP2910246A4 (fr) Composition pharmaceutique pour la prévention ou le traitement du cancer, contenant enoblock comme principe actif
MX375356B (es) Composiciones efectivas contra la conjuntivitis viral.
PL407711A1 (pl) N-Guanylowe pochodne 9-amino-5,11-dimetylo-5H-indolo[2,3-b]chinoliny, sposób ich otrzymywania i zawierające je środki farmaceutyczne
MY189372A (en) Indole derivatives
TN2017000248A1 (en) Cgrp antagonist peptides
EP2862573A4 (fr) Composition pour le traitement ou la prévention de maladies causées par une perméabilité vasculaire, contenant de l'imatinib ou un sel pharmaceutiquement acceptable de celui-ci en tant que principe actif
EP3360581A4 (fr) Composition pharmaceutique pour prévenir ou traiter un cancer comprenant un inhibiteur de plrg1 (régulateur pléiotropique 1) comme principe actif